ImmunoFree, Inc, a US-based company that was founded in 2023 to improve the lives of transplant patients by using new stem cell technology to eliminate the need for immunosuppressive medications without fear of organ rejection, announced on Tuesday that it has named Dr Ephraim Fuchs as its new chief medical officer.
In the new role, Dr Fuchs will manage all of the company's medical and scientific matters and be responsible for the development of the ImmunoFree tolerance protocol for the 1,000,000 plus transplant recipients globally who can benefit from the elimination of immunosuppressive medications.
Dr Fuchs co-founded ImmunoFree and serves as the professor of Oncology & Immunology at the Johns Hopkins University School of Medicine.
enGene names new chief financial officer and head of Business Development
The American Board of Medical Specialties names new members of the board of directors
MedGenome names new Advisory Board chairman
MentalHealth.com names new Dr Jesse Hanson as new clinical director
Element Biosciences names new director
BD names new executive vice president and chief medical officer
Fuse Oncology names new chief technology officer
Halia Therapeutics names new vice president Regulatory Affairs and new senior medical director
Rivus Pharmaceuticals names new chief medical officer
K36 Therapeutics names new chief medical officer
Kyverna Therapeutics' fifth KYV-101 Investigational New Drug application receives US FDA approval
Nereid Therapeutics names new president and chief executive officer